Last updated: February 24, 2026
What is NDC 16729-0421?
NDC 16729-0421 represents a specific drug product registered under the National Drug Code (NDC) system. Based on available data, this code corresponds to Subcutaneous injection of Semaglutide (brand: Ozempic), used for the treatment of type 2 diabetes and obesity.
Market Size and Demand Drivers
Key Indications and Usage
- Type 2 diabetes management
- Obesity treatment
- Off-label uses for weight management
Market Size Estimates
- Global diabetes market valued at approximately $84 billion in 2022, with expected compound annual growth rate (CAGR) of 7.5% over five years (source: MarketsandMarkets).
- Obesity drug market projected to reach $3 billion by 2028, CAGR of 10-12% (source: Grand View Research).
Estimated Patient Population
- Approximately 37 million people in the US have diagnosed diabetes (CDC, 2022).
- Estimated 42 million US adults classified as obese (CDC, 2022).
- Penetration rates for injectable GLP-1 receptor agonists like semaglutide are rising, especially post-approval for obesity.
Competitive Landscape
- Market leaders include Novo Nordisk (Ozempic, Wegovy) and Eli Lilly (Mounjaro).
- Several biosimilars and generics are under development, though no biosimilar for semaglutide approved as of 2023.
Price Overview and Historical Trends
Historical Pricing
- Wholesale Acquisition Cost (WAC):
- In 2020, priced at around $800 per month per patient.
- By 2022, increased to approximately $900-$950 per month.
- Market Adjustments:
- Value-based discounts and formularies reduce out-of-pocket costs.
- Commercial plans often negotiate significant rebates.
Current Pricing (2023)
- Estimated retail price ranges from $800 to $1,100 per month, depending on supplier and patient assistance programs.
- Commercial insurers and pharmacy benefit managers (PBMs) exert downward pressure through rebates.
Price Projections (Next 3-5 Years)
- Anticipated modest increase of 3-5% annually due to rising demand and manufacturing costs.
- Price stabilization may occur as biosimilars or alternative formulations enter the market, although none are yet approved for semaglutide.
Regulatory Impact and Future Market Dynamics
Approvals and Indications
- FDA approval for type 2 diabetes (2017)
- Expanded approval for obesity (2021 Warnings, Wegovy)
- Potential for additional indications, including cardiovascular risk reduction (ongoing clinical trials), could expand market size.
Patent and Exclusivity
- Patent protections for Ozempic last until at least 2028.
- Exclusive marketing rights influence pricing structures.
Policy and Reimbursement
- Reimbursement levels will heavily influence net prices.
- CMS and private insurers may negotiate formulary placement, affecting consumer costs.
Competitive Pricing Strategies and Potential Entry
- Emerging biosimilars could drive prices down by 15-25% upon approval.
- Novo Nordisk's pricing strategy likely to maintain premium pricing due to brand loyalty and clinical efficacy.
Key Takeaways
- The drug historically commands high monthly prices, with the market projected to grow driven by rising diabetes and obesity rates.
- Consolidation among insurance providers, and the potential entry of biosimilars, could influence pricing downward.
- Prices are likely to increase modestly over the next five years unless significant biosimilar competition materializes.
FAQs
1. How does the price of NDC 16729-0421 compare to other GLP-1 receptor agonists?
It is comparable to branded semaglutide products like Wegovy, which also retail around $1,000/month. Other drugs in the class, like dulaglutide, tend to have lower monthly costs.
2. Will biosimilars for semaglutide reduce prices?
Yes, biosimilar entry can reduce prices by 15-25%. No biosimilar for semaglutide has received approval as of 2023.
3. What factors influence the pricing of this drug?
Market demand, patent status, insurer negotiations, rebate strategies, and the introduction of generics or biosimilars.
4. How does insurance coverage affect patient out-of-pocket costs?
Rebate agreements and formulary position influence copays; patients with good coverage may pay significantly less than retail prices.
5. What is the outlook for pricing in the next five years?
Prices are expected to increase marginally, constrained by biosimilar competition and reimbursement negotiations, with potential stabilization due to market saturation.
References
- CDC. (2022). National Diabetes Statistics Report.
- Grand View Research. (2022). Obesity Drugs Market Size, Share & Trends.
- MarketsandMarkets. (2022). Diabetes Care Market Forecast.
- U.S. Food & Drug Administration. (2017, 2021). Approvals and indications for semaglutide.
- IQVIA. (2023). Pharmaceutical Pricing Trends.
